Cargando…

Prostate Cancer Detection with mpMRI According to PI-RADS v2 Compared with Systematic MRI/TRUS-Fusion Biopsy: A Prospective Study

Background: mpMRI assesses prostate lesions through their PI-RADS score. The primary goal of this prospective study was to demonstrate the correlation of PI-RADS v2 score and the volume of a lesion with the presence and clinical significance of prostate cancer (PCa). The secondary goal was to determ...

Descripción completa

Detalles Bibliográficos
Autores principales: Sauck, Anja, Keller, Isabelle, Hainc, Nicolin, Pfofe, Denis, Najafi, Arash, John, Hubert, Hohmann, Joachim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416664/
https://www.ncbi.nlm.nih.gov/pubmed/36006067
http://dx.doi.org/10.3390/tomography8040169
_version_ 1784776534079307776
author Sauck, Anja
Keller, Isabelle
Hainc, Nicolin
Pfofe, Denis
Najafi, Arash
John, Hubert
Hohmann, Joachim
author_facet Sauck, Anja
Keller, Isabelle
Hainc, Nicolin
Pfofe, Denis
Najafi, Arash
John, Hubert
Hohmann, Joachim
author_sort Sauck, Anja
collection PubMed
description Background: mpMRI assesses prostate lesions through their PI-RADS score. The primary goal of this prospective study was to demonstrate the correlation of PI-RADS v2 score and the volume of a lesion with the presence and clinical significance of prostate cancer (PCa). The secondary goal was to determine the extent of additionally PCa in inconspicuous areas. Methods: All 157 patients underwent a perineal MRI/TRUS-fusion prostate biopsy. Targeted biopsies as well as a systematic biopsy were performed. The presence of PCa in the probes was specified by the ISUP grading system. Results: In total, 258 lesions were biopsied. Of the PI-RADS 3 lesions, 24% were neoplastic. This was also true for 36.9% of the PI-RADS 4 lesions and for 59.5% of the PI-RADS 5 lesions. Correlation between ISUP grades and lesion volume was significant (p < 0.01). In the non-suspicious mpMRI areas carcinoma was revealed in 19.7% of the patients. Conclusions: The study shows that the PI-RADS v2 score and the lesion volume correlate with the presence and clinical significance of PCa. However, there are two major points to consider: First, there is a high number of false positive findings. Second, inconspicuous mpMRI areas revealed PCa.
format Online
Article
Text
id pubmed-9416664
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94166642022-08-27 Prostate Cancer Detection with mpMRI According to PI-RADS v2 Compared with Systematic MRI/TRUS-Fusion Biopsy: A Prospective Study Sauck, Anja Keller, Isabelle Hainc, Nicolin Pfofe, Denis Najafi, Arash John, Hubert Hohmann, Joachim Tomography Article Background: mpMRI assesses prostate lesions through their PI-RADS score. The primary goal of this prospective study was to demonstrate the correlation of PI-RADS v2 score and the volume of a lesion with the presence and clinical significance of prostate cancer (PCa). The secondary goal was to determine the extent of additionally PCa in inconspicuous areas. Methods: All 157 patients underwent a perineal MRI/TRUS-fusion prostate biopsy. Targeted biopsies as well as a systematic biopsy were performed. The presence of PCa in the probes was specified by the ISUP grading system. Results: In total, 258 lesions were biopsied. Of the PI-RADS 3 lesions, 24% were neoplastic. This was also true for 36.9% of the PI-RADS 4 lesions and for 59.5% of the PI-RADS 5 lesions. Correlation between ISUP grades and lesion volume was significant (p < 0.01). In the non-suspicious mpMRI areas carcinoma was revealed in 19.7% of the patients. Conclusions: The study shows that the PI-RADS v2 score and the lesion volume correlate with the presence and clinical significance of PCa. However, there are two major points to consider: First, there is a high number of false positive findings. Second, inconspicuous mpMRI areas revealed PCa. MDPI 2022-08-16 /pmc/articles/PMC9416664/ /pubmed/36006067 http://dx.doi.org/10.3390/tomography8040169 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sauck, Anja
Keller, Isabelle
Hainc, Nicolin
Pfofe, Denis
Najafi, Arash
John, Hubert
Hohmann, Joachim
Prostate Cancer Detection with mpMRI According to PI-RADS v2 Compared with Systematic MRI/TRUS-Fusion Biopsy: A Prospective Study
title Prostate Cancer Detection with mpMRI According to PI-RADS v2 Compared with Systematic MRI/TRUS-Fusion Biopsy: A Prospective Study
title_full Prostate Cancer Detection with mpMRI According to PI-RADS v2 Compared with Systematic MRI/TRUS-Fusion Biopsy: A Prospective Study
title_fullStr Prostate Cancer Detection with mpMRI According to PI-RADS v2 Compared with Systematic MRI/TRUS-Fusion Biopsy: A Prospective Study
title_full_unstemmed Prostate Cancer Detection with mpMRI According to PI-RADS v2 Compared with Systematic MRI/TRUS-Fusion Biopsy: A Prospective Study
title_short Prostate Cancer Detection with mpMRI According to PI-RADS v2 Compared with Systematic MRI/TRUS-Fusion Biopsy: A Prospective Study
title_sort prostate cancer detection with mpmri according to pi-rads v2 compared with systematic mri/trus-fusion biopsy: a prospective study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416664/
https://www.ncbi.nlm.nih.gov/pubmed/36006067
http://dx.doi.org/10.3390/tomography8040169
work_keys_str_mv AT sauckanja prostatecancerdetectionwithmpmriaccordingtopiradsv2comparedwithsystematicmritrusfusionbiopsyaprospectivestudy
AT kellerisabelle prostatecancerdetectionwithmpmriaccordingtopiradsv2comparedwithsystematicmritrusfusionbiopsyaprospectivestudy
AT haincnicolin prostatecancerdetectionwithmpmriaccordingtopiradsv2comparedwithsystematicmritrusfusionbiopsyaprospectivestudy
AT pfofedenis prostatecancerdetectionwithmpmriaccordingtopiradsv2comparedwithsystematicmritrusfusionbiopsyaprospectivestudy
AT najafiarash prostatecancerdetectionwithmpmriaccordingtopiradsv2comparedwithsystematicmritrusfusionbiopsyaprospectivestudy
AT johnhubert prostatecancerdetectionwithmpmriaccordingtopiradsv2comparedwithsystematicmritrusfusionbiopsyaprospectivestudy
AT hohmannjoachim prostatecancerdetectionwithmpmriaccordingtopiradsv2comparedwithsystematicmritrusfusionbiopsyaprospectivestudy